ADCT vs. AMPH, SNDX, ETNB, COGT, SPRY, PAHC, ABCL, EVO, TLRY, and XERS
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), 89BIO (ETNB), Cogent Biosciences (COGT), ARS Pharmaceuticals (SPRY), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Evotec (EVO), Tilray Brands (TLRY), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.
ADC Therapeutics vs. Its Competitors
Amphastar Pharmaceuticals (NASDAQ:AMPH) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.
Amphastar Pharmaceuticals currently has a consensus target price of $31.60, indicating a potential upside of 3.20%. ADC Therapeutics has a consensus target price of $7.75, indicating a potential upside of 152.03%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Amphastar Pharmaceuticals.
In the previous week, Amphastar Pharmaceuticals had 14 more articles in the media than ADC Therapeutics. MarketBeat recorded 15 mentions for Amphastar Pharmaceuticals and 1 mentions for ADC Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 1.34 beat ADC Therapeutics' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.
65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Amphastar Pharmaceuticals has a net margin of 18.64% compared to ADC Therapeutics' net margin of -220.00%. Amphastar Pharmaceuticals' return on equity of 20.76% beat ADC Therapeutics' return on equity.
Amphastar Pharmaceuticals has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500.
Summary
Amphastar Pharmaceuticals beats ADC Therapeutics on 11 of the 16 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:ADCT) was last updated on 9/1/2025 by MarketBeat.com Staff
Free ADCT Stock Alerts